Skip to Content

Ceftriaxone Side Effects

Not all side effects for ceftriaxone may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

For the Consumer

Applies to ceftriaxone: injection powder for solution

In addition to its needed effects, some unwanted effects may be caused by ceftriaxone. In the event that any of these side effects do occur, they may require medical attention.

If any of the following side effects occur while taking ceftriaxone, check with your doctor or nurse immediately:

More common
  • Black, tarry stools
  • chest pain
  • chills
  • cough
  • fever
  • painful or difficult urination
  • shortness of breath
  • sore throat
  • sores, ulcers, or white spots on the lips or in the mouth
  • swollen glands
  • unusual bleeding or bruising
  • unusual tiredness or weakness
Less common
  • Diarrhea
  • Abdominal or stomach cramps or tenderness
  • back, leg, or stomach pains
  • bleeding gums
  • bloating
  • blood in the urine or stools
  • bloody nose
  • bluish color
  • changes in skin color
  • clay-colored stools
  • convulsions
  • cough or hoarseness
  • dark urine
  • diarrhea, watery and severe, which may also be bloody
  • difficulty with breathing
  • difficulty with swallowing
  • dizziness
  • fast, irregular, pounding, or racing heartbeat or pulse
  • feeling of discomfort
  • feeling of warmth
  • fever with or without chills
  • general body swelling
  • general feeling of tiredness or weakness
  • headache
  • hives
  • increased sweating
  • increased thirst
  • inflammation of the joints
  • itching
  • loss of appetite
  • lower back or side pain
  • muscle aches
  • nausea or vomiting
  • noisy breathing
  • nosebleeds
  • pain
  • pale skin
  • pinpoint red spots on the skin
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • rash
  • redness of the face, neck, arms, and occasionally, upper chest
  • shortness of breath
  • skin rash
  • swelling of the foot or leg
  • swollen lymph glands
  • tenderness
  • tightness in the chest
  • troubled breathing with exertion
  • unpleasant breath odor
  • unusual weight loss
  • vomiting of blood
  • watery or bloody diarrhea
  • wheezing
  • yellowing of the eyes or skin
Incidence not known
  • Blistering, peeling, or loosening of the skin
  • chest pain
  • coughing up blood
  • decrease in the amount of urine
  • excessive muscle tone
  • increased menstrual flow or vaginal bleeding
  • muscle stiffness, tension, or tightness
  • nosebleeds
  • paralysis
  • prolonged bleeding from cuts
  • red irritated eyes
  • red or black, tarry stools
  • red or dark brown urine
  • red skin lesions, often with a purple center
  • restlessness
  • skin rash with a general disease
  • swelling
  • trouble sitting still
  • unpleasant breath odor

Some of the side effects that can occur with ceftriaxone may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

  • Acid or sour stomach
  • belching
  • bloated
  • change in taste
  • dizziness
  • excess air or gas in the stomach or intestines
  • full feeling
  • headache
  • heartburn
  • indigestion
  • itching of the vagina or genital area
  • loss of taste
  • pain during sexual intercourse
  • passing gas
  • stomach discomfort, upset, or pain
  • thick, white vaginal discharge with no odor or with a mild odor
Incidence not known
  • Hives or welts
  • redness, swelling, or soreness of the tongue
  • swelling or inflammation of the mouth

For Healthcare Professionals

Applies to ceftriaxone: injectable powder for injection, intramuscular kit, intravenous solution


Gastrointestinal side effects have included diarrhea (2.7%); nausea, vomiting, and dysgeusia (less than 1%); gallbladder sludge, biliary lithiasis, colitis, flatulence, dyspepsia, abdominal pain (less than 0.1%); cholelithiasis, and pseudomembranous colitis. Rare cases of pancreatitis, possibly secondary to biliary obstruction, have been reported. Stomatitis and glossitis have been reported during postmarketing experience.[Ref]

Both pseudocholelithiasis (biliary "sludging") and true cholelithiasis (ceftriaxone-containing gallstone) have been reported in association with ceftriaxone dosages greater than 2 grams per day. A false-positive hepatobiliary scan occurred in a patient receiving ceftriaxone. A repeat test two weeks after discontinuation of ceftriaxone was normal.

Ceftriaxone-associated diarrhea may, in rare cases, be associated with C difficile pseudomembranous colitis. If diarrhea occurs and is unresponsive to discontinuation of the drug and/or standard therapy, pseudomembranous colitis should be considered.[Ref]


Ceftriaxone-associated neutropenia and thrombocytopenia are reversible upon discontinuation of therapy. Fever and rash often accompany these conditions.

Nineteen cases (10 adults, 9 children) of immune hemolytic anemia have been reported, 9 of which were fatal. Symptoms may occur within minutes or weeks of drug administration. Initial symptoms included tachycardia, dyspnea, pallor, back or leg pain, and decrease in hemoglobin levels.[Ref]

Hematologic side effects have included eosinophilia (6%), thrombocytosis (5.1%), and leukopenia (2.1%). Anemia, hemolytic anemia, neutropenia, lymphopenia, thrombocytopenia, and prothrombin time prolongation have been reported in less than 1% of patients. Agranulocytosis, lymphocytosis, leukocytosis, monocytosis, basophilia, and decreased prothrombin time have been reported in less than 0.1% of patients. Cephalosporins as a class have also been associated with aplastic anemia, hemorrhage and pancytopenia.[Ref]


A case of occupational contact dermatitis has been reported in a nurse who prepared cephalosporin solutions for administration to patients. The dermatitis resolved after the nurse stopped preparing the solutions.

A case of an acute generalized exanthematic pustulosis (AGEP) has been reported following administration of ceftriaxone. This was characterized by the appearance of an erythematous and generalized scarlatiniform rash with plaques covered by small nonfollicular pustules on the thighs, abdomen, and lower extremities. Ceftriaxone was discontinued and the AGEP was completely resolved after two weeks.

An allergic reaction manifested by itching, maculopapular rash, hyperthermia, flushing has been reported in a patient with X-linked agammaglobulinemia in the absence of IgE. T cell involvement was proposed as the mechanism.

Cross-sensitivity with other cephalosporins and penicillins may occur; however, the incidence is unknown.[Ref]

Hypersensitivity side effects have included rash (1.7%), pruritus, fever, chills, anaphylaxis, and serum sickness. Allergic pneumonitis, allergic reaction, contact dermatitis, and acute generalized exanthematic pustulosis have also been reported. Cephalosporin class antibiotics have been associated with Stevens-Johnson syndrome, erythema multiforme, drug fever, serum sickness-like reaction, and toxic epidermal necrolysis.[Ref]


Renal side effects have included elevations of BUN (1.2%), creatinine, urinary casts, renal precipitations, and nephrolithiasis. Cephalosporins as a class have been associated with renal dysfunction and toxic nephropathy.[Ref]

Patients with underlying renal dysfunction may be at higher risk for these conditions.[Ref]


Local side effects have included pain, induration, and tenderness in 1% of patients. Phlebitis has occurred in less than 1% of patients after intravenous administration. Intramuscular injection has been associated with warmth, tightness and induration in 17% of patients receiving the 350 mg/mL solution and 5% of patients receiving the 250 mg/mL solution. Lidocaine 1% may be used as a diluent to decrease pain at the injection site.[Ref]


Genitourinary side effects have included moniliasis, vaginitis, glycosuria, and hematuria. Oliguria has been reported during postmarketing experience.[Ref]


Hepatic side effects have included elevations of SGOT (3.1%), SGPT (3.3%), alkaline phosphatase (less than 1%), bilirubin (less than 1%), and jaundice (less than 0.1%). Cephalosporins as a class have been associated with hepatic dysfunction including cholestasis.[Ref]

Nervous system

Nervous system side effects have included headache, dizziness, and seizures. Cephalosporin class antibiotics have been associated with reversible hyperactivity and hypertonia.[Ref]


Endocrine side effects have included diaphoresis and flushing (less than 1%).[Ref]


Respiratory side effects have rarely included bronchospasm and epistaxis.[Ref]


Cardiovascular side effects have included palpitations (less than 0.1%) and thrombus.[Ref]


Immunologic side effects have included life-threatening and fatal cases of immune hemolytic anemia, with symptoms of pallor, tachycardia, hypotension, dyspnea, and severe back pain. Most of these patients had preexisting hematologic or immunodeficiency disorders, and 1 had Crohn's disease.[Ref]


Dermatologic side effects have included exanthema, allergic dermatitis, urticaria, edema, and isolated cases of severe cutaneous adverse reactions (erythema multiforme, Stevens-Johnson syndrome, or Lyell's syndrome/toxic epidermal necrolysis) during postmarketing experience.[Ref]


Other side effects associated with cephalosporin class antibiotics have included superinfection, positive direct Coombs' test, false-positive test for urinary glucose, and elevated LDH.[Ref]


1. Pletz MW, Rau M, Bulitta J, et al. "Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers." Antimicrob Agents Chemother 48 (2004): 3765-72

2. Bickford CL, Spencer AP "Biliary sludge and hyperbilirubinemia associated with ceftriaxone in an adult: case report and review of the literature." Pharmacotherapy 25 (2005): 1389-95

3. Valesova M, Mailer H, Havlik J, Hulinska D, Hercogova J "Long-term results in patients with lyme arthritis following treatment with ceftriaxone." Infection 24 (1996): 98-102

4. Nadelman RB, Arlin Z, Wormser GP "Life-threatening complications of empiric ceftriaxone therapy for seronegative Lyme disease." South Med J 84 (1991): 1263-5

5. Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez Vazquez JM "Ceftriaxone-associated biliary pseudolithiasis in adults." Lancet 2 (1989): 165

6. Thomas P, Daly S, Misan G, Steele T "Comparison of the efficacy and adverse effect profile of cefotaxime and ceftriaxone in ICU patients with susceptible infections." Diagn Microbiol Infect Dis 15 (1992): 89-97

7. Simon N, Dussol B, Sampol E, et al. "Population pharmacokinetics of ceftriaxone and pharmacodynamic considerations in haemodialysed patients." Clin Pharmacokinet 45 (2006): 493-501

8. Lopez AJ, O'Keefe P, Morrissey M, Pickleman J "Ceftriaxone-induced cholelithiasis." Ann Intern Med 115 (1991): 712-4

9. Eichmann A, Weidmann G, Havas L "One-dose treatment of acute uncomplicated gonorrhoea of male patients with ceftriaxone Ro 13-9904, a new parenteral cephalosporin: a dose-range finding pilot study." Chemotherapy 27 (1981): 62-9

10. Meyboom RH, Kuiper H, Jansen A "Ceftriaxone and reversible cholelithiasis." BMJ 297 (1988): 858

11. Zinberg J, Chernaik R, Coman E, Rosenblatt R, brandt LJ "Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis." Am J Gastroenterol 86 (1991): 1251-4

12. Valesova H, Mailer J, Havlik J, Hulinska D, Hercogova J "Long-term results in patients with Lyme arthritis following treatment with ceftriaxone." Infection 24 (1996): 98-102

13. Arredondo JL, Diaz V, Gaitan H, Maradiegue E, Oyarzun E, Paz R, Reynal JL, Stamm W, Zambrano D "Oral clindamycin and ciprofloxacin versus intramuscular ceftriaxone and oral doxycycline in the treatment of mild-to-moderate pelvic inflammatory disease in outpatients." Clin Infect Dis 24 (1997): 170-8

14. "Product Information. Rocephin (ceftriaxone)." Roche Laboratories, Nutley, NJ.

15. Rohacova H, Hancil J, Hulinska D, Mailer H, Havlik J "Ceftriaxone in the treatment of lyme neuroborreliosis." Infection 24 (1996): 88-90

16. Rivkin AM "Hepatocellular enzyme elevations in a patient receiving ceftriaxone." Am J Health Syst Pharm 62 (2005): 2006-2010

17. Maranan MC, Gerber SI, Miller GG "Gallstone pancreatitis caused by ceftriaxone." Pediat Inf Dis J 17 (1998): 662-3

18. Dattwyler RJ, Luft BJ, Kunkel MJ, Finkel MF, Wormser GP, Rush TJ, Grunwaldt E, Agger WA, Franklin M, Oswald D, Cockey L, Maladorno D "Ceftriaxone compared with doxycycline for the treatment of acute disseminated Lyme disease." N Engl J Med 337 (1997): 289-94

19. Bailey RR, Walker RJ, Cook HB "Ceftriaxone-induced colitis." N Z Med J 98 (1985): 969

20. Wormser GP "Clinical practice. Early Lyme disease." N Engl J Med 354 (2006): 2794-801

21. Moskovitz, BL "Clinical adverse effects during ceftriaxone therapy." Am J Med 77 (1984): 84-8

22. Kirejczyk WM, Crowe HM, Mackay IM, Quintiliani R, Cronin EB "Disappearing "gallstones": biliary pseudolithiasis complicating ceftriaxone therapy." Am J Roentgenol 159 (1992): 329-30

23. Nahata MC, Barson WJ "Ceftriaxone: a third-generation cephalosporin." Drug Intell Clin Pharm 19 (1985): 900-6

24. Rey D, Martin T, Albert A, Pasquali JL "Ceftriaxone-induced granulopenia related to a peculiar mechanism of granulopoiesis inhibition." Am J Med 87 (1989): 591-2

25. Hull RL, Brandon D "Thrombocytopenia possibly caused by structurally related third-generation cephalosporins." Ann Pharmacother 25 (1991): 135-6

26. Duncan CJ, Evans TJ, Seaton RA "Ceftriaxone-related agranulocytosis during outpatient parenteral antibiotic therapy." J Antimicrob Chemother 65 (2010): 2483-4

27. "Hemolysis from Ceftriaxone." Med Lett Drugs Ther 44 (2002): 100-101

28. Fallon BA, Keilp JG, Corbera KM, et al. "A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy." Neurology (2007):

29. Baciewicz AM, Skiest DJ, Weinshel EL "Ceftriaxone-associated neutropenia." Drug Intell Clin Pharm 22 (1988): 826-7

30. Ramakrishnan K, Scheid DC "Diagnosis and management of acute pyelonephritis in adults." Am Fam Physician 71 (2005): 933-42

31. Kudva-Patel V, White E, Karnani R, Collins MH, Assa'ad AH "Drug reaction to ceftriaxone in a child with X-linked agammaglobulinemia." J Allergy Clin Immunol 109(5 Pt 1) (2002): 888-9

32. Moallem HJ, Garratty G, Wakeham M, Dial S, Oligario A, Gondi A, Rao SP, Fikrig S "Ceftriaxone-related fatal hemolysis in an adolescent with perinatally acquired human immunodeficiency virus infection." J Pediatr 133 (1998): 279-81

33. Filipe P, Almeida RSLS, Rodrigo FG "Occupational allergic contact dermatitis from cephalosporins." Contact Dermatitis 34 (1996): 226

34. Lewis JD "Liquid sucralfate in the management of aphthous ulcers." Am Fam Physician 64 (2001): 737

35. Baniasadi S, Fahimi F, Mansouri D "Serum sickness-like reaction associated with cefuroxime and ceftriaxone." Ann Pharmacother 41 (2007):

36. Thiella G, Bucci L, Agrati AM, Palmieri G "Nonfatal anaphylactic shock following an unusual sensitization." J Occup Med 31 (1989): 490

37. Romano A, Mayorga C, Torres MJ, Artesani MC, Suau R, Sanchez F, Perez E, Venuti A, Blanca M "Immediate allergic reactions to cephalosporins: Cross-reactivity and selective responses." J Allerg Clin Immunol 106 (2000): 1177-83

38. Grasberger H, Otto B, Loeschke K "Ceftriaxone-associated nephrolithiasis." Ann Pharmacother 34 (2000): 1076-7

39. Toll LL, Lee M, Sharifi R "Cefoxitin-induced interstitial nephritis." South Med J 80 (1987): 274-5

40. Gargollo PC, Barnewolt CE, Diamond DA "PEDIATRIC CEFTRIAXONE NEPHROLITHIASIS." J Urol 173 (2005): 577-578

41. Haskell RJ, Fujita NK, Stevenson JA, Border WA "Cefoxitin-induced interstitial nephritis." Arch Intern Med 141 (1981): 1557

42. Hayward CJ, Nafziger AN, Kohlhepp SJ, Bertino JS "Investigation of bioequivalence and tolerability of intramuscular ceftriaxone injections by using 1% lidocaine, buffered lidocaine, and sterile water diluents." Antimicrob Agents Chemother 40 (1996): 485-7

43. Mattis LE, Saavedra JM, Shan H, Shirey RS, Powell E, Oliva-Hemker MM "Life-threatenting ceftriaxone-induced immune hemolytic anemia in a child with Crohn's disease." Clin Pediatr (Phila) 43 (2004): 175-8

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.